
Alnylam Pharmaceuticals, Inc.: updates and filings
Price
$143.82
November 20, 2026Market cap $19.1B
What Ploutos Investor adds for Alnylam Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2008
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 29, 2026next Jan 29, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
October 2026
July 2026
April 2026
February 2026
January 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 5, 2026Officer or director change, other material eventsForm8-K
- Oct 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 29, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 29, 2026Results of operationsForm8-K
- Jul 30, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 30, 2026Results of operationsForm8-K
- May 27, 2026Officer or director change, shareholder voteForm8-K
- May 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 30, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 30, 2026Results of operationsForm8-K
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 6, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 6, 2026Additional annual meeting materialFormDEFA14A
- Apr 6, 2026Annual meeting proxy statementFormDEF 14A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 4, 2026Officer or director changeForm8-K
- Feb 12, 2026Shares registered for employeesFormS-8
- Feb 12, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 12, 2026Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 5, 2026 | 8-K | Officer or director change, other material events | Document |
| Oct 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 29, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 29, 2026 | 8-K | Results of operations | Document |
| Jul 30, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 30, 2026 | 8-K | Results of operations | Document |
| May 27, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 30, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 30, 2026 | 8-K | Results of operations | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 6, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 6, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 6, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 4, 2026 | 8-K | Officer or director change | Document |
| Feb 12, 2026 | S-8 | Shares registered for employees | Document |
| Feb 12, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 12, 2026 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 9, 2002.
The full analysis
What do Alnylam Pharmaceuticals's filings show?
The filings are where every one of Alnylam Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.